Related Experiment Videos
Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice
G Goodarzi1, M Watabe, K Watabe
1Department of Medical Microbiology/Immunology, Southern Illinois University School of Medicine, Springfield 62708.
Abstract:
Results of recent studies in our laboratory have suggested a potential role for antisense oligodeoxyribonucleotides (oligo(dN)s) as therapeutic agents in the treatment of human hepatitis B virus infection. As a first step towards assessing the potential utility of oligo(dN) in therapy, we have examined the organ distribution, stability and toxicity of a phosphorothioated oligo(dN) (S-oligo) of 20 nucleotides in length which was administered to mice via different routes. Among the various organs analysed, the liver retained the highest amount of S-oligo (1.3-2 per cent of the total injection) at the peak time (10-30 min) regardless of the route of injection. However, the S-oligo appeared to be degraded in the liver to about 40 per cent of its original length within 30 min of injection, presumably by the action of 3' exonucleases. Injection of doses of up to 5 mg kg-1 of S-oligo had no apparent toxic effects on the mice.
Insights
Antisense oligodeoxyribonucleotides show potential for treating hepatitis B virus infection. Studies in mice indicate the liver retains these compounds, but they degrade quickly, with no observed toxicity at tested doses.
Area of Science:
- Pharmacology
- Hepatology
- Virology
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern.
- Antisense oligodeoxyribonucleotides (oligo(dN)s) are being explored as potential antiviral therapeutics.
- Previous laboratory studies suggest oligo(dN)s may be effective against HBV.
Purpose of the Study:
- To evaluate the organ distribution, stability, and toxicity of a specific phosphorothioated oligo(dN) (S-oligo).
- To assess the therapeutic potential of S-oligo for treating HBV infection.
Main Methods:
- Administration of a 20-nucleotide phosphorothioated oligo(dN) (S-oligo) to mice via different routes.
- Analysis of S-oligo organ distribution and degradation over time.
- Assessment of potential toxic effects following S-oligo administration.
Main Results:
- The liver demonstrated the highest retention of S-oligo (1.3-2% of total injection) within 10-30 minutes post-injection, irrespective of administration route.
- S-oligo degraded significantly in the liver to approximately 40% of its original length within 30 minutes, likely due to 3' exonuclease activity.
- No apparent toxic effects were observed in mice receiving S-oligo doses up to 5 mg/kg.
Conclusions:
- The liver is a primary target organ for S-oligo administration.
- Rapid degradation of S-oligo in the liver may limit its therapeutic efficacy for HBV.
- Further research is warranted to optimize oligo(dN) stability and delivery for effective HBV therapy.